CompanyBDTXNasdaqCambridge, MA

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics is a clinical-stage oncology company developing small-molecule kinase inhibitors targeting oncogenic mutations.

SEC EDGAR ClinicalTrials.gov blackdiamondtherapeutics.com

10-QSep 18Latest SEC filing, period to Jun 30

Aug 5Latest story

August 2026

Black Diamond reports Phase 2 silevertinib data, plans FDA meeting on pivotal path

Aug 5Quarterly updateBlack Diamond Therapeutics, Inc.silevertinib